786 related articles for article (PubMed ID: 26965076)
1. Vaccines for established cancer: overcoming the challenges posed by immune evasion.
van der Burg SH; Arens R; Ossendorp F; van Hall T; Melief CJ
Nat Rev Cancer; 2016 Apr; 16(4):219-33. PubMed ID: 26965076
[TBL] [Abstract][Full Text] [Related]
2. Current challenges for cancer vaccine adjuvant development.
Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic cancer vaccines.
Saxena M; van der Burg SH; Melief CJM; Bhardwaj N
Nat Rev Cancer; 2021 Jun; 21(6):360-378. PubMed ID: 33907315
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of immune escape in the cancer immune cycle.
Tang S; Ning Q; Yang L; Mo Z; Tang S
Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
Overwijk WW
Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
[TBL] [Abstract][Full Text] [Related]
6. In situ vaccination for the treatment of cancer.
Hammerich L; Bhardwaj N; Kohrt HE; Brody JD
Immunotherapy; 2016; 8(3):315-30. PubMed ID: 26860335
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer vaccine therapy for hematologic malignancies: An evolving era.
Nahas MR; Rosenblatt J; Lazarus HM; Avigan D
Blood Rev; 2018 Jul; 32(4):312-325. PubMed ID: 29475779
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic cancer vaccines.
Melief CJ; van Hall T; Arens R; Ossendorp F; van der Burg SH
J Clin Invest; 2015 Sep; 125(9):3401-12. PubMed ID: 26214521
[TBL] [Abstract][Full Text] [Related]
9. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
Durrant LG; Pudney V; Spendlove I; Metheringham RL
Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
[TBL] [Abstract][Full Text] [Related]
10. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
11. Overcoming tumor immune evasion with an unique arbovirus.
Lyday B; Chen T; Kesari S; Minev B
J Transl Med; 2015 Jan; 13():3. PubMed ID: 25592450
[TBL] [Abstract][Full Text] [Related]
12. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors.
Arens R
Adv Immunol; 2012; 114():217-43. PubMed ID: 22449784
[TBL] [Abstract][Full Text] [Related]
13. Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3-5, 2011.
Aptsiauri N; Cabrera T; Garcia-Lora A; Garrido F
Cancer Immunol Immunother; 2012 May; 61(5):739-45. PubMed ID: 22350069
[No Abstract] [Full Text] [Related]
14. Creating therapeutic cancer vaccines: notes from the battlefield.
Overwijk WW; Restifo NP
Trends Immunol; 2001 Jan; 22(1):5-7. PubMed ID: 11286676
[TBL] [Abstract][Full Text] [Related]
15. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
16. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.
Mohme M; Riethdorf S; Pantel K
Nat Rev Clin Oncol; 2017 Mar; 14(3):155-167. PubMed ID: 27644321
[TBL] [Abstract][Full Text] [Related]
17. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
18. Rationale for immunological approaches to breast cancer therapy.
Monnot GC; Romero P
Breast; 2018 Feb; 37():187-195. PubMed ID: 28629632
[TBL] [Abstract][Full Text] [Related]
19. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Gajewski TF
Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
